ReviewOsteoporosis and sarcopenia2025
Vaccine hesitancy and bone health: Musculoskeletal sequelae of vaccine-preventable diseases.
Review in Osteoporosis and sarcopenia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccine hesitancy threatens global health by diminishing herd immunity and permitting the return of vaccine-preventable diseases (VPDs) including poliomyelitis, measles and coronavirus disease 2019 (COVID-19). These infections carry short-term and long-term musculoskeletal consequences, such as paralysis, limb deformities, septic or reactive arthritis, osteomyelitis and chronic pain, that place an ever increasing burden on orthopaedic services. This narrative review synthesizes clinical and epidemiological evidence linking sub-optimal immunization to orthopaedic morbidity caused by major VPDs. Outbreak data show that low vaccination coverage precipitates spikes in invasive bacterial disease after varicella, post-polio deformities, tetanus-related fractures, rubella-associated arthritis and COVID-19-related avascular necrosis (AVN). This impact is amplified in rapidly ageing regions such as Asia, where the population ≥ 60 years will nearly double by 2050, significantly increasing the prevalence of sarcopenia and osteoporosis that exacerbate VPD complications. Although orthopaedic surgeons are not primary vaccinators, they routinely manage these downstream effects and hold a trusted position in society from which they are able to strongly advocate for immunization. Integrating brief vaccine counselling, perioperative vaccination checks, and public health initiatives into orthopaedic practice can improve uptake and reduce preventable disability. Strengthening immunization programs and countering hesitancy are essentially critical not only for infection control but also for safeguarding a rapidly declining global musculoskeletal health. A coordinated strategy involving public-health authorities, primary-care providers, and specialists, including orthopaedic surgeons, is essential to mitigate vaccine hesitancy and its orthopaedic sequelae.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.